Posts tagged ‘biotech marketing consulting’
Pieter Droppert will be attending the Biotechnology Industry Association (BIO) international convention that takes place in Washington DC from June 27-30, 2011.
Pieter has shared on Biotech Strategy Blog, his top 10 sessions at BIO 2011. Topics at the meeting he plans to hear more about include personalized medicine, biomarkers, biosimilars, biologics and tissue engineering. Biotech regions from around the world will also be sharing how they promote innovation.
As he notes in his post, at BIO he will be applying the “law of two feet.” Simply put this means if the session you are in isn’t delivering the goods or ROI, it’s OK to walk out and go to another one. That is another one of the advantages of following the live-tweets at a conference, you can readily see if there’s a more interesting session going on!
Pieter will be writing about the news from BIO 2011 on Biotech Strategy Blog.
At the recent annual meeting of the American Association for Cancer Research (AACR) in Orlando, Sally Church on Pharma Strategy Blog, chose a poster by patient advocate, Leslie Hammersmith as “My AACR Poster of the Day.” A hard won accolade in a field of more than 5000 posters!
One of the attractions of this poster, (and you can read more about why Sally chose it on Pharma Strategy Blog) was its use of social media, and particular quick response (QR) codes.
QR codes are a matrix bar code that is now easily readable by smart phones, you can readily find apps for the iPhone. By scanning the QR code using the camera in the phone you are automatically directed to further information – whether it be a copy of the poster, a scientific paper or a website.
As Sally said in her blog post about Leslie’s poster, “The clever use of QR codes made me want it on all the science posters too.” A few other science researchers did have QR codes on their posters, and we see this as a social media trend that will expand.
We will be adding a QR code to our next print run of business cards, will you?
Nanotechnology is expected to provide major breakthroughs in how drugs cross the blood-brain barrier and reach into tumors. That promise is already starting to be seen.
Research by Julia Ljubimova and her team at Cedars-Sinai Medical Center was recently published in the AACR journal, Cancer Research. They showed that biodegradable nanoparticles containing trastuzumab (herceptin), dramatically reduced HER2/neu protein activity in mice containing human HER2/neu positive breast tumors.
As Sally Church in her thoughtful post about this research on Pharma Strategy Blog, states, “it will be most interesting to see if this idea is developed clinically in human trials and whether the results will be reproducible or not.”
Nanotechnology and the development of nanoparticles that deliver drugs more effectively and with less toxicity, is an area that all new products professionals should be watching.